Paratek Pharmaceuticals (Paratek Pharmaceuticals) Operating Cash Flow per Share : $-0.42 (TTM As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals Operating Cash Flow per Share?

Paratek Pharmaceuticals's operating cash flow per share for the three months ended in Jun. 2023 was $-0.03. Paratek Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.42.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 32.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 18.90% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 17.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Paratek Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

PRTK' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -15.6 Med: 18.15 Max: 79.6
Current: 32.2

During the past 13 years, Paratek Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 79.60% per year. The lowest was -15.60% per year. And the median was 18.15% per year.

PRTK's 3-Year OCF Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.6 vs PRTK: 32.20

Paratek Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Paratek Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Operating Cash Flow per Share Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Cash Flow per Share

Get a 7-Day Free Trial

-2.58

-4.09

-2.34

-1.00

-1.22

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.27	-0.23	-0.36	0.20	-0.03

Competitive Comparison of Paratek Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Paratek Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paratek Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Paratek Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Paratek Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (A: Dec. 2022 )	=	Cash Flow from Operations (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	-66.141	/	54.388
	=	-1.22

Paratek Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (Q: Jun. 2023 )	=	Cash Flow from Operations (Q: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
	=	-1.776	/	57.282
	=	-0.03

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42

Paratek Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Executives

Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz	director	C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh	director, officer: CEO	75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel	officer: CLO, General Counsel & Sec.	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow	officer: President & Chief Commercial	C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner	officer: Chief Development & Regulatory	C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie	director	101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann	director	LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham	director, officer: Exec. Chairman of the Board	890 WINTER STREET, WALTHAM MA 02451
James D Dondero	10 percent owner	300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan	officer: Chief Financial Officer	75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199